If I had $20,000 to invest in ASX 200 shares right now, I would not be trying to guess the next short-term winner.
Instead, I would focus on businesses that sit inside long-term structural demand trends: healthcare, wealth management, and essential services that Australians continue to rely on regardless of economic conditions.
I think that approach can help smooth out some of the noise that comes from markets reacting to interest rates, sentiment shifts, and short-term headlines.
Here is how I would allocate that $20,000 today.
Sigma Healthcare Ltd (ASX: SIG)
One part of the portfolio would go to a business that operates at the centre of Australia’s healthcare supply chain.
Sigma Healthcare is deeply embedded in pharmaceutical distribution and the supply of medicines to community pharmacies across the country.
What I like about this type of business is the essential nature of demand. Medicines are not discretionary. They are required regardless of economic conditions, which can provide a level of resilience over time.
The distribution model also benefits from scale. Once a national supply network is established, it becomes difficult for smaller players to compete on efficiency, coverage, and reliability.
It is not the most exciting part of the market, but I think it is one of the most durable.
Hub24 Ltd (ASX: HUB)
Another portion of the $20,000 would go to a business that is closely tied to the growth of Australia’s financial advice and superannuation system.
Hub24 provides a technology platform used by financial advisers to manage client portfolios, reporting, administration, and investment operations.
I think this is one of those businesses that benefits from complexity rather than simplicity. As client needs become more personalised and regulatory requirements increase, advisers need better systems to manage their workload efficiently.
That creates demand for platforms that can simplify administration and improve visibility across portfolios.
Once a financial adviser integrates a platform into their workflow, it can become difficult to replace without significant disruption. That kind of embedded usage can support long-term growth.
Cochlear Ltd (ASX: COH)
The final portion of the $20,000 would go to a business operating in a very different part of the healthcare sector.
Cochlear is a global leader in hearing implant technology. It operates in a market driven more by medical need and demographics than by economic cycles. Hearing loss becomes more common with age, which creates a long-term structural demand base across developed and emerging markets.
What stands out to me is the combination of medical technology leadership and long product lifecycles. These are not low-cost or easily replaceable solutions. They require clinical trust, regulatory approval, and long-term support infrastructure.
That tends to create strong competitive positioning over time, although execution in innovation and global rollout remains critical.
Foolish takeaway
If I were investing $20,000 into ASX 200 shares this month, I would want exposure to different types of long-term demand rather than concentrating on a single theme.
Each business operates in a different part of the economy, but all three share a common feature: they are tied to needs that do not disappear when markets get uncertain.
That is the type of foundation I would want when putting $20,000 to work for the long term.
The post Where I’d invest $20,000 into ASX 200 shares this month appeared first on The Motley Fool Australia.
Should you invest $1,000 in Cochlear right now?
Before you buy Cochlear shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Cochlear shares have jumped 23% in a month: Is there more upside ahead?
- Here are the top 10 ASX 200 shares today
- 5 biggest losers on the ASX 200 in FY26
- WiseTech shares are now the ASX 200’s biggest loser. What next?
- Cochlear shares are up 23% in a month. Buy, hold or sell?
Motley Fool contributor Grace Alvino has positions in Hub24. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Hub24. The Motley Fool Australia has recommended Cochlear and Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.